REVERSE-ENGINEERING NATURE

IMPROVING HEALTH OUTCOMES IN INNOVATIVE WAYS BASED ON NATURE’S WISDOM

 

BUSINESS
MODEL

Impact Biomedical drives mission-oriented research and development that advances drug discovery and development for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. Other exciting technologies include breakthrough alternative sugar in the aim to combat diabetes and Functional Fragrances Formulation (3F) for industrial and medical application, amongst others. The first product in 3F’s suite of functional fragrances is 3F Mosquito which is made up of specialised oils sourced from botanicals that mosquitoes avoid. The business model of Impact Biomedical revolves mainly around two methodologies – Licensing and Sales Distribution.

bioimpact icon.png

Licensing

 

Impact Biomedical develop valuable and unique patented technologies which could be licensed to pharmaceutical companies and venture capitalists in exchange for an agreed payment (fee or royalty). This interest will rise as the validating data becomes available.

bioimpact icon.png

Sales Distribution

 

On the other hand, Impact Biomedical has sister companies that have in place distribution networks on a global basis. Impact Biomedical will engage in private labelling to go into production of products for sales generation. We plan to expand our geographical presence globally and intend to launch more products to add on to the flagship product range. 

bm copy.jpg
 

FROM JUST 5 OUT OF 35 PREVIOUSLY RESTRUCTURED COMPANIES

APPROX. CURRENT MARKET CAP OVER

USD 19.9 BILLION

AND GROWING

BRINGING IN PROFITS OF OVER

USD 1 BILLION

PER ANNUM

 
 
Chan Heng Fai Full Body.jpg

Game Changer | Unicorn Maker | Financial Architect | ​Restructuring Expert

book2.png

ZH International Limited

Formerly Known as Heng Fai Enterprises

 

Hong Kong Stock Exchange Listed

Restructured from Bankruptcy

book1.png

Global Medical REIT

 

Hong Kong Stock Exchange Listed

Founded and Funded from Ground Zero

book4.png

Singhaiyi Ltd

Formerly Known as SingXpress Land

Singapore Exchange Listed
Restructured from Bankruptcy

book3.png

China Gas

Hong Kong Exchange Listed
Restructured from Bankruptcy

American Pacific Bank

NASDAQ Listed
Recapitalized from Bankruptcy

CHAN HENG FAI
EXECUTIVE CHAIRMAN

DIRECTORS, OFFICERS & ADVISORS

Chan Heng Fai

John 'JT' Thatch

William Harrison Lyerly, JR.

Daryl Thompson

Christina Glendening

Moe Chan

Ronald Wei.png

Ronald Wei

Frank D Heuszel

Scott Truesdell

Danny Lim

Michael Gershon

Jason Grady

Dr. Roscoe M. Moore

Robert Trapp

 

Products in the Pipeline

Mosquito Technology.png

3F (Functional  Fragrance Formulation) is a unique formulation of specialized ingredients (e.g. terpenes) from botanical sources with  demonstrated effect as an insect repellent and an antimicrobial.


3F Mosquito Repellent
3F repellent contains botanical ingredients that mosquitos avoid. These ingredients are scientifically  proven* to affect the mosquito’s receptors, essentially making the insect blind to a human’s presence.  This can be utilized as a stand-alone repellent or as an additive in detergents, lotions, shampoo, and
other substances to provide mosquito protection.


3F Antimicrobial
3F antimicrobial contains botanical ingredients known to kill viruses. These ingredients are scientifically proven* to inhibit viral replication. This can be utilized as a stand-alone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics, and other substances.

*Source: Company Data on File

Equivir.png

Equivir/Nemovir technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols (e.g. Myricetin, Hesperetin, Piperine) which have demonstrated antiviral effects with
additional potential application as health supplements or medication. Polyphenols are sourced from fruits, vegetables, and other natural substances.


Myricetin is a member of the flavonoid class of polyphenolic compounds with antioxidant properties.
Hesperitin is a flavanone and Piperine is an alkaloid, commonly found in black pepper.

Linebacker.png

LineBacker is a platform of small molecule X-bonded polyphenols. X-bonding is a molecular tuning
technique that modifies a natural compound to induce potency, efficacy, bioavailability, and
trans-membrane permeability while maintaining safety, toxicity, and tolerability.


Natural polyphenols have demonstrated strong potential in treating and preventing a range of diseases
by inhibiting TNF- and indication specific causes (e.g. neurology, anti-inflammatory, oncology).


Two novel discrete LineBacker molecules have been synthesized and characterized including
in vitro testing.

LAETOSE

Laetose technology is derived from a unique combination of sugar and inositol, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone.


Use of Laetose in a daily diet, compared to sugar, could result in 30% lower sugar consumption and lower glycemic index/load*

*Source: Company data on file

 
 
 
 
 

FUTURE PROJECTS

Unveiling Soon

 

RELATED COMPANY

vivacitas.png

About Vivacitas Oncology Inc. 

Vivacitas Oncology Inc. (“Vivacitas”) was co-founded in 2015 by the late Dr. Rubinfeld and is singularly focused on innovative approaches to combating those cancers that have proven to be frustratingly resistant to current treatment modalities.

 

MEDIA

 
Videos
Press Release
Title
Date

DSS Expands Nutraceutical Product Lines through Impact BioMedical’s Investment in Nano Nutraceutical Contract Manufacturer Nano9

18 Jan 2021

DSS’s Impact BioMedical Receives Notice of Allowance for 3F Biofragrance Patent

13 Jan 2021

DSS Wholly Owned Subsidiary Impact BioMedical Announces Exclusive Distribution Agreement with BioMed Technology

22 Dec 2020

Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned
Subsidiary - Innate Immune, Inc.

1 Oct 2020

Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance

17 Sep 2020

Impact BioMedical Initiates Bioplastics Research Collaboration with One of World’s Largest Plastic Manufacturers

8 Sep 2020

COMPLETION OF THE US$50 MILLION SHARE SWAP

23 Aug 2020

DOCUMENT SECURITY SYSTEMS, INC.’S SHAREHOLDERS APPROVE PROPOSED US$50.0 MILLION SHARE SWAP

11 Aug 2020

Impact Biomedical initiates Quantum Research Program to solve the Patent Cliff

26 Jul 2020

IMPACT BIOMEDICAL ACHIEVES COVID-19 SUCCESS WITH EQUIVIR AND 3F BIOFRAGRANCE RESPONSES TO QUERIES RAISED BY THE SGX-ST

24 Jun 2020

 
 

CONTACT
US

OUR ADDRESS

United States

Document Security Systems, Inc

200 Canal View Blvd, Suite 104 | Rochester, NY 14623

(1) 301 971 3955T /  (1) 301 971 3940

Singapore

7 Temasek Boulevard #29-01B Suntec Tower One Singapore 038987

(65) 6333 9181

Hong Kong

7/Floor, Skyway Centre, 23 Queen’s Road West Sheung Wan, Hong Kong

(852) 2711 1808

Back to Top

BACK TO TOP